ClinicalTrials.gg
CompletedNCT02025452Updated Mar 27, 2017

Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis

A Phase 4 interventional study of Rapid diagnostic and Probiotic in Acute Gastroenteritis, sponsored by Jeffrey Pernica. Completed at 3 sites in Botswana. Open to participants aged 2 Months to 60 Months. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by Jeffrey Pernica · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
2 Months to 60 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing probiotic in Diarrhea — none open to participants now, none under way, none of them phase 3. Probiotic · Diarrhea.

Enrollment
13th of 20
76 · median 102
Started
2014
the only one that year
Phase 4
Only one
of the 20
Registered
12th of 20
by date
Lead sponsor
1 of 20
Jeffrey Pernica

Among the 20 studies testing probiotic in Diarrhea, this one is the 13th largest by enrollment, is the only one that started in 2014, is the only one in phase 4, and was the 12th registered.

Diarrhea

880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

None of the 20 studies testing probiotic in Diarrhea is open now. The open studies under Diarrhea, anywhere →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Diarrhea studies recruiting now, 21 (46%) set no upper age limit and 23 (50%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 2 Months to 60 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing probiotic in Diarrhea as a file.
02

Study summary

Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have viral gastroenteritis and so not treated with antibiotics - but they may indeed have a treatable cause for their illness. We will conduct a randomized trial to see if rapid testing using novel methods to identify potentially treatable causes of diarrhoea leads to improved outcomes. We will also be randomizing children to probiotic therapy versus placebo (the standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a pilot trial, necessary before embarking on a large multi-centre trial.

03

Conditions studied

  • Acute Gastroenteritis

Keywords

  • diarrhoea
  • gastroenteritis
  • rapid diagnostics
  • probiotics
  • sub-Saharan Africa
04

Who can participate

Ages eligible
2 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute non-bloody gastroenteritis

Exclusion criteria

Exclusion Criteria:

  • diarrhoea > 14 days
  • sepsis, pneumonia, UTI, meningitis requiring empiric antibiotic therapy
  • , IBD
  • known link to another patient with diarrhoea of defined aetiology
  • transferred in already on antimicrobials
  • live outside study area
  • children with severe acute malnutrition will be eligible for diagnostic arm but not probiotic arm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    Rapid diagnostics and probiotic

    Other: Rapid diagnostic · Dietary Supplement: Probiotic

  • Placebo comparator
    Rapid diagnostics and placebo

    Other: Rapid diagnostic · Other: Placebo

  • Experimental
    Delayed diagnostics and probiotic

    Dietary Supplement: Probiotic

  • Placebo comparator
    Delayed diagnostics and placebo

    Other: Placebo

Interventions

  • OtherRapid diagnostic

    Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.

  • Dietary supplementProbiotic

    Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months

  • OtherPlacebo

    Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.

06

What researchers measure

Primary outcomes

  1. Height z-score (HAZ) adjusted for initial HAZ

    Time frame: 60 days post-enrollment

Secondary outcomes

  1. mortality

    Time frame: 60 days post-enrollment

  2. environmental enteropathy score

    Time frame: 60 days post-enrollment

  3. duration of diarrhoea

    Note that presence of diarrhoea will be checked daily during admission. Total duration of diarrhoea will be verified with the caregiver by telephone 7 days after the participant was discharged home.

    Time frame: estimated average duration ~ 4 days.

  4. Weight z-score (WAZ) adjusted for initial WAZ

    Time frame: 60 days after enrolment

07

Study locations

3 sites
  • Princess Marina Hospital
    Gaborone, Botswana
  • Scottish Livingstone Hospital
    Molepolole, Botswana
  • Bamalete Lutheran Hospital
    Ramotswa, Botswana
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2013
First posted
Jan 1, 2014
Start
Mar 2014
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Last update
Mar 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02025452
Lead sponsor
Jeffrey Pernica
Collaborators
Grand Challenges Canada, BioGaia AB
Responsible party
Jeffrey Pernica (Head, Division of Pediatric Infectious Disease, Hamilton Health Sciences Corporation) — Sponsor-investigator
First posted
Jan 1, 2014
Start date
Mar 2014
Primary completion
Nov 2014
Completion
Dec 2014
Last update
Mar 27, 2017

Study contacts

Jeffrey Pernica, MD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion